In patients ≥12 years of age with BBS,
IMCIVREE delivered early, significant, and sustained hunger reduction1
Hunger scale in the BBS clinical trial2

- Patients ≥12 years of age who were able to self-report their hunger (n=14) recorded their daily maximal hunger in a diary, which was then assessed by the Daily Hunger Questionnaire Item 2
- Hunger was scored on an 11-point scale from 0 (“not hungry at all”) to 10 (“hungriest possible”)
References: 1. Data on file. Rhythm Pharmaceuticals, Inc. Boston, MA. 2. IMCIVREE [prescribing information]. Boston, MA. Rhythm Pharmaceuticals, Inc. 3. Haws RM et al. Contemp Clin Trials Commun. 2021;22:100780.